Bristol-Myers Squibb Co: U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C (Businesswire)

Press/Media: Press / Media

PeriodFeb 5 2016

Media coverage

1

Media coverage

  • TitleBristol-Myers Squibb Co: U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C (Businesswire)
    Media name/outletAvanza Bank AB
    CountrySweden
    Date2/5/16
    PersonsFred Poordad